A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Trial and Open-Label Extension Study to Evaluate the Efficacy and Safety of Add-On Therapy With Empagliflozin for Patients With Inadequately Controlled Type 2 DiabetesMellitus in the Combination Treatment With Metformin and Alogliptin

Phase 3 study to assess the Efficacy and Safety of CT-L02-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Alogliptin Combination Therapy.

Start Date18 Jul 2025

Sponsor / Collaborator

Celltrion, Inc.

CTR20250730

/ CompletedNot Applicable

苯甲酸阿格列汀片（25mg）在中国健康受试者中空腹给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验

[Translation] A randomized, open-label, single-dose, two-sequence, two-period, double-crossover bioequivalence study of alogliptin benzoate tablets (25 mg) in Chinese healthy subjects under fasting conditions

主要研究目的：按有关生物等效性试验的规定，选择Takeda Pharmaceutical Company Limited为持证商的苯甲酸阿格列汀片（商品名：尼欣那，规格：25mg）为参比制剂，对石家庄四药有限公司生产并提供的受试制剂苯甲酸阿格列汀片（规格：25mg）进行空腹给药人体生物等效性试验，比较受试制剂中药物的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内，评价两种制剂在空腹给药条件下的生物等效性。次要研究目的：观察健康受试者口服受试制剂苯甲酸阿格列汀片（规格：25mg）和参比制剂苯甲酸阿格列汀片（商品名：尼欣那，规格：25mg）的安全性。

[Translation]

Main purpose of study: According to the relevant provisions of bioequivalence test, Takeda Pharmaceutical Company Limited was selected as the reference preparation for alogliptin benzoate tablets (trade name: Nisina, specification: 25mg), and the test preparation alogliptin benzoate tablets (specification: 25mg) produced and provided by Shijiazhuang Siyao Co., Ltd. was used for fasting human bioequivalence test, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting conditions. Secondary purpose of study: To observe the safety of oral administration of the test preparation alogliptin benzoate tablets (specification: 25mg) and the reference preparation alogliptin benzoate tablets (trade name: Nisina, specification: 25mg) in healthy subjects.

Start Date24 Mar 2025

Sponsor / Collaborator

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

CTR20250729

/ CompletedNot Applicable

苯甲酸阿格列汀片（25mg）在中国健康受试者中餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验

主要研究目的：按有关生物等效性试验的规定，选择Takeda Pharmaceutical Company Limited为持证商的苯甲酸阿格列汀片（商品名：尼欣那，规格：25mg）为参比制剂，对石家庄四药有限公司生产并提供的受试制剂苯甲酸阿格列汀片（规格：25mg）进行餐后给药人体生物等效性试验，比较受试制剂中药物的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内，评价两种制剂在餐后给药条件下的生物等效性。次要研究目的：观察健康受试者口服受试制剂苯甲酸阿格列汀片（规格：25mg）和参比制剂苯甲酸阿格列汀片（商品名：尼欣那，规格：25mg）的安全性。

[Translation]

Main purpose of study: According to the relevant provisions of bioequivalence test, Takeda Pharmaceutical Company Limited was selected as the reference preparation for alogliptin benzoate tablets (trade name: Nisina, specification: 25mg), and the test preparation alogliptin benzoate tablets (specification: 25mg) produced and provided by Shijiazhuang Siyao Co., Ltd. was used for human bioequivalence test after meal administration. The difference between the absorption rate and absorption extent of the drug in the test preparation and the reference preparation was compared to see whether it was within an acceptable range, and to evaluate the bioequivalence of the two preparations under the condition of postprandial administration. Secondary purpose of study: To observe the safety of oral administration of the test preparation alogliptin benzoate tablets (specification: 25mg) and the reference preparation alogliptin benzoate tablets (trade name: Nisina, specification: 25mg) to healthy subjects.

Start Date23 Mar 2025

Sponsor / Collaborator

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

100 Clinical Results associated with Alogliptin Benzoate

100 Translational Medicine associated with Alogliptin Benzoate

100 Patents (Medical) associated with Alogliptin Benzoate

771

Literatures (Medical) associated with Alogliptin Benzoate

01 Feb 2026·LUMINESCENCE

Fluorescein‐Based Charge–Transfer Fluorimetric Method for Quantification of Gliptin Drugs: Comprehensive Greenness, Blueness, and Sustainability Assessment

Article

Author: Shahin, Reem Y. ; Attia, Tamer Z. ; Taha, Hager M. ; Noureldeen, Deena A. M.

ABSTRACT:

A green, sustainable, and highly sensitive fluorimetric method was developed for the quantitative determination of the antidiabetic agents alogliptin, saxagliptin, and vildagliptin in bulk powders and commercial formulations. The assay relies on charge–transfer complexation with fluorescein in acetate buffer at drug‐specific pH values, producing enhanced fluorescence at 513 nm ( λex = 470 nm). Under optimized conditions, linear responses were obtained within 2.00–50.00 μg/mL for saxagliptin, 1.00–30.00 μg/mL for vildagliptin, and 1.00–31.25 μg/mL for alogliptin, with detection limits of 0.54, 0.27, and 0.23 μg/mL, respectively. The corresponding quantification limits were 1.63, 0.81, and 0.70 μg/mL. The method exhibited excellent correlation coefficients across all ranges and was validated in accordance with ICH guidelines. Application to pharmaceutical tablets yielded results consistent with reported reference methods, confirming accuracy and precision without significant statistical differences. Greenness and sustainability were evaluated using multiple assessment tools (AGSA, GAPI, AGREE, MoGAPI, Eco‐scale, CACI, BAGI, CaFRI, and MA tool), confirming the eco‐friendly profile of the assay. The proposed method provides a reliable, green alternative for routine quality control of gliptins in pharmaceutical preparations.

30 Jan 2026·BMC CANCER

The role of CD26 in breast cancer and its pan-cancer analysis.

Article

Author: Huang, Jiaqi ; Zhang, Chenrong ; Li, Yixing ; Gong, Qiuyu ; Liu, Bohao ; Zhang, Guangjian ; Wang, Jizhao ; Zhu, Xingzhuo ; Gao, Shan ; Zhang, Jingyi ; Wang, Zhiyu ; Tao, Runyi ; Zhao, Yilong

BACKGROUND:

CD26 (DPP4) is shown in literature to be implicated in multiple tumors and antitumor immunity, yet its pan-cancer and context-dependent roles remain imprecisely defined. This study comprehensively characterizes the clinical relevance of CD26 and its association with invasion-related features and immunotherapy-relevant immune infiltration and response-associated biomarkers, and to validate key findings in breast cancer cells.

METHODS:

The integrated pan-cancer analysis of CD26 was performed using public databases, assessing its expression patterns, associations with cancer staging and prognostic value. Co-expression and protein-interaction data were used for GO/KEGG enrichment to infer potential biological pathways. Correlations between CD26 and immune cell infiltration, cancer-associated fibroblasts (CAFs), immune checkpoints, tumor mutational burden (TMB), microsatellite instability (MSI), and neoantigen load were systematically evaluated. R software and online bioinformatics tools were employed. Additionally, qPCR, western blot and other in-vitro experiments compared CD26 expression in MCF-7 breast cancer cells and MCF-10A normal breast epithelial cells, and examined the effects of pharmacologic CD26 inhibition (alogliptin) on proliferation, invasion, and MMP9 expression in vitro.

RESULTS:

CD26 exhibited broad but low tissue specificity and was significantly upregulated in multiple malignancies compared with normal tissues, particularly in highly aggressive tumors (P < 0.01). Higher CD26 expression was associated with advanced pathological stage and adverse prognosis in several tumor types (p < 0.01), including breast cancer, while exhibiting a favorable prognostic association in a subset of tumors, indicating context-dependent relationships. Functional enrichment suggested involvement of CD26-related networks in chemokine signaling and EMT-related processes. CD26 expression correlated with estimated immune infiltration in 34 of 38 tumor types, including CD4⁺ and CD8⁺ T cells and CAFs, and was associated with multiple immune checkpoints, as well as TMB, MSI and neoantigens in selected cancers. In vitro, CD26 was elevated in MCF-7 versus MCF-10A cells (p < 0.05), and alogliptin treatment reduced MCF-7 cell proliferation and invasion (p < 0.05), accompanied by decreased MMP9 expression (p < 0.05).

CONCLUSIONS:

This study presents an integrative pan-cancer framework linking CD26 expression to immune infiltration, together with in vitro observations in breast cancer cells, offering a comprehensive pan-cancer and experimental characterization of CD26. CD26 might be a novel prognostic biomarker candidate and therapeutic target to counteract tumor development in highly aggressive cancer.

02 Jan 2026·Expert Opinion On Drug Safety

Exploring SGLT-2 inhibitors and sarcopenia in FAERS: a post-marketing surveillance study

Article

Author: Tang, Guowen ; Yuan, Jie ; Ye, Yangli ; Kuai, Zheng ; Zhang, Xiaoyi ; Gao, Lihong

BACKGROUND:

The sodium-dependent glucose transporters 2 inhibitors (SGLT-2i) is associated with body weight loss but the composition of the losing weight remains unclear.

RESEARCH DESIGN AND METHODS:

Disproportionality analyses, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi- item gamma Poisson shrinker (MGPS) algorithms, were employed to quantify the signals of SGLT-2i-associated musculoskeletal and connective tissue disorders AEs.

RESULTS:

The search retrieved a total of 3,206 cases of musculoskeletal and connective tissue disorder-related AEs during the reporting period. This included 1,061 cases for Canagliflozin, 1,052 cases for Dapagliflozin, 1,074 cases for Empagliflozin, and 19 cases for Ertugliflozin. Fifteen preferred terms (PTs) with significant disproportionality were retained. No musculoskeletal and connective tissue system-related AE signals were reported for Ertugliflozin. We identified a risk of muscle necrosis with Canagliflozin use, a risk of sarcopenia with Dapagliflozin use, and a chance of muscle atrophy with Dapagliflozin and Empagliflozin prescriptions. Most cases occurred within the first month after SGLT-2i initiation, and AEs can persist beyond 360 days of use.

CONCLUSIONS:

Our study identified potential new musculoskeletal and connective tissue disorder-related AE signals associated with SGLT-2 inhibitors.

News (Medical) associated with Alogliptin Benzoate

29 Aug 2025

·www.einpresswire.com

July - September 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Ajovy (fremanezumab-vfrm) Emgality (galcanezumab-gnlm) Nurtec ODT (rimegepant) Ubrelvy (ubrogepant) Vyepti (eptinezumab-jjmr) Hypertension The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in March 2025 to include information about the risk of hypertension. Example: Ajovy labeling Apriso (mesalamine) Asacol (mesalamine) Asacol HD (mesalamine) Azulfidine (sulfasalazine) Azulfidine EN-Tabs (sulfasalazine) Canasa (mesalamine) Colazal (balsalazide disodium) Delzicol (mesalamine) Dipentum (osalazine sodium) Giazo (balsalazide disodium) Lialda (mesalamine) Rowasa (mesalamine) Pentasa (mesalamine) Severe cutaneous adverse reactions The Warnings and Precautions section of the labeling was updated November 2021 to include severe cutaneous adverse reactions. Example: Delzicol labeling Avastin (bevacizumab) Mvasi (bevacizumab-awwb) Zirabev (bevacizumab-bvzr) Pancreatitis FDA determined that no action is necessary at the time based on available information. Avastin (bevacizumab) Mvasi (bevacizumab-awwb) Zirabev (bevacizumab-bvzr) Anaphylactic shock The "Warnings and Precautions" section of the labeling was updated between September 2022 and February 2023 to include anaphylactoid/anaphylactic reactions. Example: Avastin labeling Ayvakit (avapritinib) Photosensitivity reaction The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in March 2023 to include information about photosensitivity. Ayvakit labeling Azacitidine Onureg (azacitidine) Vidaza (azacitidine) Generic products containing azacitidine Pericarditis The "Adverse Reactions" section of the labeling was updated between September 2022 and June 2023 to include pericarditis. Example: Vidaza labeling FDA determined that no action is necessary at the time based on available information for Onureg. Bavencio (avelumab) Imfinzi (durvalumab) Libtayo (cemiplimab-rwlc) Keytruda (pembrolizumab) Opdivo (nivolumab) Tecentriq (atezolizumab) Yervoy (ipilimumab) Tumour lysis syndrome FDA determined that no action is necessary at the time based on available information. Cymbalta (duloxetine hydrochloride) Drizalma Sprinkle (duloxetine hydrochloride) Generic products containing duloxetine hydrochloride Anosmia, Hyposmia This issue is posted as two individual newly identified safety signal (NISS) entries in the January-March 2022 quarter, to reflect the focus on the potential signals of anosmia and hyposmia, separately. Darzalex (daratumumab) Darzalex Faspro (daratumumab and hyaluronidase-fihj) Blood stem cell transplant failure FDA determined that no action is necessary at the time based on available information. Dipeptidyl peptidase-4 (DPP-4) inhibitors Glyxambi (empagliflozin and linagliptin) Janumet (metformin hydrochloride and sitagliptin phosphate) Janumet XR (metformin hydrochloride and sitagliptin phosphate) Jentadueto (linagliptin and metformin hydrochloride) Jentadueto XR (linagliptin and metformin hydrochloride) Kazano (alogliptin and metformin hydrochloride) Kombiglyze XR (metformin hydrochloride and saxagliptin) Nesina (alogliptin) Onglyza (saxagliptin) Oseni (alogliptin and pioglitazone) Steglujan (ertugliflozin and sitagliptin) Tradjenta (linagliptin) Trijardy XR (empagliflozin, linagliptin and metformin hydrochloride) Qtern (saxagliptin and dapagliflozin) Generic products containing dipeptidyl peptidase-4 inhibitors Tubulointerstitial nephritis The "Adverse Reactions" section of the labeling was updated between March 2022 and June 2022 for products containing alogliptin and sitagliptin to include tubulointerstitial nephritis. Example: Janumet labeling FDA determined that no action is necessary for products containing linagliptin and saxagliptin at the time based on available information. *An administrative error resulted in the omission of Januvia from the list of product names after the initial quarterly report was posted. Dupixent (dupilumab) Angioedema The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in December 2021 to include angioedema. Dupixent labeling Glucagon-like peptide-1 (GLP-1) analogues Adlyxin (lixisenatide) Bydureon (exenatide) Bydureon BCise (exenatide) Byetta (exenatide) Ozempic (semaglutide) Rybelsus (semaglutide) Saxenda (liraglutide) Soliqua 100/33 (insulin glargine and lixisenatide injection) Trulicity (dulaglutide) Victoza (liraglutide) Wegovy (semaglutide) Xultophy 100/3.6 (insulin degludec and liraglutide injection) Generic products containing glucagon-like peptide-1 analogues Gallbladder related disorders The "Warnings and Precautions", "Adverse Reactions", and "Patient Counseling Information" sections of the GLP-1 analogues labeling were updated between March 2022 and June 2022 to include information about acute gallbladder disease. Example: Adlyxin labeling FDA has determined that the last approved labeling for Saxenda and Wegovy is adequately labeled for acute gallbladder disease, and that no further regulatory action is needed at this time. Gonadotropin releasing hormone (GnRH) analogues Fensolvi (leuprolide acetate) Lupron Depot-PED (leuprolide acetate) Supprelin LA (histrelin acetate) Synarel (nafarelin acetate) Triptodur (triptorelin) Idiopathic intracranial hypertension The "Warnings", "Precautions", and "Adverse Reactions" sections of the labeling were updated in April 2022 to include idiopathic intracranial hypertension. Example: Fensolvi labeling Jakafi (ruxolitinib phosphate) Herpes simplex virus (HSV) reactivation and/or disseminated HSV The "Dosage and Administration", "Warnings and Precautions", and "Adverse Reactions" sections of the labeling were updated in January 2023 to include information about herpes simplex and herpes zoster infections. Jakafi labeling Ibrance (palbociclib) Kisqali (ribociclib) Kisqali Femara Co-Pack (letrozole and ribociclib) Embolic and thrombotic events, venous The "Adverse Reactions" section of the Ibrance labeling was updated in December 2024 to include venous thromboembolism. Ibrance labeling FDA determined that no action is necessary at the time for Kisqali and Kisqali Femara Co-Pack based on available information. Ocrevus (ocrelizumab) Myocardial infarction FDA determined that no action is necessary at the time based on available information. Potassium Chloride Product preparation error The “Warnings” section of the labeling was updated in December 2022 to include information about fatal cardiac adverse reactions with intravenous administration of undiluted potassium chloride. Praxbind (idarucizumab) Wrong dose errors The carton labeling and "Dosage and Administration" sections of the labeling were revised in February 2022 to clarify the number of vials included in each carton and the recommended dosing. Praxbind labeling Qbrexza (glycopyrronium tosylate) Accidental exposure to product The container label, carton labeling, "Dosage and Administration", "Warnings and Precautions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in October 2022 to include information about accidental exposure. Qbrexza labeling Qbrexza (glycopyrronium tosylate) Urinary retention The “Warnings and Precautions”, “Adverse Reactions”, and “Patient Counseling Information” sections of the labeling were updated in October 2022 to include information about new or worsening urinary retention. Qbrexza labeling Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Farxiga (dapagliflozin) Glyxambi (empagliflozin and linagliptin) Invokamet (canagliflozin and metformin hydrochloride) Invokamet XR (canagliflozin and metformin hydrochloride) Invokana (canagliflozin) Jardiance (empagliflozin) Qtern (saxagliptin and dapagliflozin) Steglatro (ertugliflozin) Steglujan (ertugliflozin and sitagliptin) Segluromet (ertugliflozin and metformin hydrochloride) Synjardy (empagliflozin and metformin hydrochloride) Synjardy XR (empagliflozin and metformin hydrochloride) Trijardy XR (empagliflozin, linagliptin and metformin hydrochloride) Xigduo XR (dapagliflozin and metformin) Generic products containing sodium-glucose cotransporter-2 (SGLT-2) inhibitors Tubulointerstitial nephritis FDA determined that no action is necessary at the time based on available information. Somatostatin Receptor Imaging Agents Detectnet (copper Cu-64 dotatate injection) Gallium Dotatoc (GA 68) Octreoscan (Indium In 111 Pentetreotide) Netspot (Gallium GA 68 Dotatate) Hypersensitivity The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in December 2021 to include hypersensitivity reactions. Example: Netspot labeling Stromectol (ivermectin) Generic products containing ivermectin Off label use FDA determined that no action is necessary at the time based on available information. Stromectol (ivermectin) Generic products containing ivermectin Neurotoxicity The "Warnings", "Adverse Reactions", and "Overdosage" sections of the labeling were updated in March 2022 to include neurotoxicity. Example: Stromectol labeling Sunosi (solriamfetol hydrochloride) Hypersensitivity FDA determined that no action is necessary at the time based on available information. Vivitrol (naltrexone) Incorrect route of product administration The container label (vial), carton labeling, "Dosage and Administration", "Warnings and Precautions", and "Description", sections of the labeling were revised in September 2022 to emphasize the appropriate route and site of administration. Vivitrol labeling Xcopri (cenobamate) Psychiatric disorders The "Adverse Reactions" section of the labeling was updated in June 2022 to include psychiatric disorders. Xcopri labeling Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug Approval

23 May 2025

·pharma.economictimes.indiatimes.com

GLP-1 diabetes drugs like Ozempic may modestly reduce cancer risks

London: Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk 's Ozempic may modestly reduce the risk of obesity-related cancers, especially colorectal cancer , according to data released on Thursday ahead of a major medical meeting. Among more than 85,000 people with type 2 diabetes and obesity treated between 2013 and 2023 and followed for an average of nearly four years, 2,501 obesity-related cancers developed in those taking GLP-1 diabetes drugs , compared with 2,671 such cancers in those treating their diabetes with drugs from a class known as DPP-4 inhibitors . After accounting for individual risk factors, those taking GLP-1 drugs had a 7 per cent lower risk of developing an obesity-related cancer and an 8 per cent lower risk of death from any cause compared to those who took a DPP-4 inhibitor, a brief summary of data to be presented at the upcoming American Society of Clinical Oncology meeting in Chicago showed. The effect was only statistically significant in women, researchers said. Other GLP-1 drugs for improving blood glucose control taken by patients in the study include Eli Lilly's Trulicity and Novo's Victoza and Rybelsus, among others. These drugs deliver a lower dose of their main ingredient compared to GLP-1 drugs designed to induce weight loss. DPP-4 inhibitors include Merck & Co's Januvia and Nesina from Takeda Pharmaceuticals. While a modestly reduced risk for 14 obesity-related cancers was evident with GLP-1 drugs, the suggestion of a protective effect was particularly strong for colorectal malignancies. There were 16 per cent fewer colon cancer cases and 28 per cent fewer rectal cancer cases in the group prescribed GLP-1 receptor agonists. Observational studies like this cannot prove that the GLP-1 drugs caused lower cancer rates. "These data are reassuring, but more studies are required to prove causation," lead study author Lucas Mavromatis, a medical student at the NYU Grossman School of Medicine in New York, said in a statement. (Reporting by Nancy Lapid; Editing by Bill Berkrot)

ASCOClinical Result

23 May 2025

·pharma.economictimes.indiatimes.com

GLP-1 diabetes drugs like Ozempic may modestly reduce cancer risks

ASCOClinical Result

100 Deals associated with Alogliptin Benzoate

External Link

KEGG	Wiki	ATC	Drug Bank
D06553	Alogliptin Benzoate	A10BH04	DB06203

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Japan	Takeda Pharmaceutical Co., Ltd.	06 Apr 2010
Diabetes Mellitus, Type 2	Japan	Teijin Pharma Ltd.	06 Apr 2010

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Coronary Syndrome	Phase 3	United States	Takeda Pharmaceutical Co., Ltd.	01 Sep 2009
Acute Coronary Syndrome	Phase 3	Japan	Takeda Pharmaceutical Co., Ltd.	01 Sep 2009
Acute Coronary Syndrome	Phase 3	Argentina	Takeda Pharmaceutical Co., Ltd.	01 Sep 2009
Acute Coronary Syndrome	Phase 3	Australia	Takeda Pharmaceutical Co., Ltd.	01 Sep 2009
Acute Coronary Syndrome	Phase 3	Austria	Takeda Pharmaceutical Co., Ltd.	01 Sep 2009
Acute Coronary Syndrome	Phase 3	Belgium	Takeda Pharmaceutical Co., Ltd.	01 Sep 2009
Acute Coronary Syndrome	Phase 3	Brazil	Takeda Pharmaceutical Co., Ltd.	01 Sep 2009
Acute Coronary Syndrome	Phase 3	Bulgaria	Takeda Pharmaceutical Co., Ltd.	01 Sep 2009
Acute Coronary Syndrome	Phase 3	Canada	Takeda Pharmaceutical Co., Ltd.	01 Sep 2009
Acute Coronary Syndrome	Phase 3	Chile	Takeda Pharmaceutical Co., Ltd.	01 Sep 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02856113 (2015-000208-25, Pubmed \| Diabetes Ther)	Phase 3	Diabetes Mellitus, Type 2	152	Alogliptin 25 mg QD	cjcetaujdg(mhfralpupu) = iroemxtpig qdnpmosglw (hzqfgxrnls, -0.63 to 0.83)	Negative	04 Mar 2025
1340-P (ADA2024)	Not Applicable	Diabetes Mellitus	-	SGLT2i	laqfozpowd(tdvujzenet) = ldlcrtdgzb nihjtcsyrs (seciwxfezw, 16.6 - 19.7)	Positive	14 Jun 2024
				DPP4i	laqfozpowd(tdvujzenet) = lytobxqvfk nihjtcsyrs (seciwxfezw, 19.1 - 21.4)
NCT05782192 (Pubmed)	Phase 3	Diabetes Mellitus, Type 2	-	Fotagliptin	bvdpbklheb(widgfaxbcy) = myzbzozjby mowomoazcy (tdcmfaondt ) View more	Positive	09 Oct 2023
				Alogliptin	bvdpbklheb(widgfaxbcy) = emstcjhbti mowomoazcy (tdcmfaondt ) View more
NCT02856113 (2015-000208-25, CTgov)	Phase 3	Diabetes Mellitus, Type 2	152	Placebo (Placebo)	agnovmbkvu(strlqdxybe) = hapirumybl spunxfyroe (mwztvyklzv, 0.2809) View more	-	19 Oct 2022
				Alogliptin Benzoate (Alogliptin 25 mg)	agnovmbkvu(strlqdxybe) = mgdswpsadz spunxfyroe (mwztvyklzv, 0.2879) View more
NCT03794336 (ACADEMIC, Pubmed \| Diabetes Obes Metab) Manual	Phase 4	Diabetes Mellitus, Type 2 \| Coronary Disease	1,088	aspirin+alogliptin	bkykzduwvg(qzjxskyyej) = jdntnqurvy gswvovukmp (xmlilwcczs, 0.4) View more	Positive	03 Feb 2022
				aspirin+acarbose	bkykzduwvg(qzjxskyyej) = iaczfnephn gswvovukmp (xmlilwcczs, 0.5) View more
NCT03794336 (EASD2021)	Phase 4	Diabetes Mellitus, Type 2 \| Cardiovascular Diseases \| Coronary Disease	-	Alogliptin 25 mg q.d.	orrmtxygpn(kbzikeszel) = Significantly lesser GI adverse events were observed with alogliptin than acarbose (8.9% vs 33.6%, P <0.0001) fzlqbvvcal (maebdtdrud ) View more	Positive	29 Sep 2021
				Acarbose 100 mg t.i.d.
NCT03231709 (TRINITY, Pubmed \| Curr Med Res Opin)	Phase 4	Diabetes Mellitus, Type 2	-	Trelagliptin	xndteqplfi(ppcmolmqgr) = avolhzrltc pidqnajwrj (pixlaqrhab )	-	02 Dec 2019
				Alogliptin	xndteqplfi(ppcmolmqgr) = wlpucwnqfk pidqnajwrj (pixlaqrhab )
NCT03501277 (CTgov)	Phase 1	-	72	alogliptin+pioglitazone+SYR-322-4833 BL (Regimen A)	jbfygxjopd(dmrvshwilq) = rbmvzkzsin evseqomisz (rlxddkmgyz, 42.87) View more	-	08 Aug 2019
				Alogliptin+pioglitazone (Regimen B)	jbfygxjopd(dmrvshwilq) = jtfwapfyhb evseqomisz (rlxddkmgyz, 44.71) View more
NCT03231709 (TRINITY, CTgov)	Phase 4	Diabetes Mellitus, Type 2	60	Trelagliptin+Alogliptin (Trelagliptin 100 mg + Alogliptin 25 mg)	zlficqfsqx = ttkezfzcyt yhyzelxiip (lakejmhfem, xwvgczimrw - cohojkgles) View more	-	10 May 2019
				Trelagliptin+Alogliptin (Alogliptin 25 mg + Trelagliptin 100 mg)	zlficqfsqx = cultcmwqtz yhyzelxiip (lakejmhfem, tcyagkbfra - kxydmlezaa) View more
NCT02771093 (TRACK, CTgov)	Phase 4	Diabetes Mellitus, Type 2	27	Trelagliptin (Trelagliptin 100 mg)	tecjflcffj(elicpdrblc) = mcezltcpyu pwpjatfsna (kyfkpesmln, vxeglpgotk - nffprocwff) View more	-	10 Dec 2018
				Alogliptin (Alogliptin 25 mg)	tecjflcffj(elicpdrblc) = qutfijekyq pwpjatfsna (kyfkpesmln, wnpswjepac - ryobzoclci) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis